Strategic Acquisition Post-acquisition by Stryker presents a large-scale distribution and integration opportunity. Leverage Stryker’s global sales channels and medical device ecosystem to accelerate adoption of AVS Pulse IVL technology across broader markets and product lines.

Peripheral Vascular Focus Specialization in severely calcified peripheral arterial disease creates a targeted selling point for hospitals and vascular labs seeking innovative IVL solutions to simplify complex calcified lesions and reduce procedure times.

Clinical Leadership Executive background and clinical credibility with founder affiliation to University of Michigan and a VP of Clinical Affairs position signal strong clinical validation potential. Use case studies and physician-led trials to drive adoption among key opinion leaders.

Funding Momentum Significant Series B and overall funding indicate investor confidence and scalable growth. Position AVS as a high-potential growth opportunity for capital equipment budgets, highlighting roadmap and next-gen platform capabilities.

Regulatory and Quality ISO 9001 and related quality frameworks, along with ongoing platform development, support ability to pursue multi-market approvals and cross-site evidence generation. Emphasize reliability and compliance to procurement and safety teams.